CagriSema and the amylin class: the next-gen weight-loss drug that ran behind its own hype
Cagrilintide is a long-acting amylin analog, and CagriSema staples it to semaglutide for a two-mechanism attack on obesity. The phase-3 REDEFINE trials landed big numbers — roughly 15% to 22% weight loss — and still managed to disappoint the people who expected 25%. That gap between a genuinely strong result and an inflated expectation is the whole story. Here is the honest, graded line between what the amylin class actually delivers and what it is being sold as.
- The phase-3 data is genuinely strong. CagriSema hit roughly 20.4% weight loss on a treatment-policy basis and up to 22.7% with full adherence in REDEFINE 1, and about 15.7% in people with type 2 diabetes in REDEFINE 2. These are real, pre-registered, thousands-of-people numbers — a legitimate advance.
- The hype ran ahead of the still-good numbers. Novo Nordisk had floated an ambition near 25%, so a 22.7% best case read as a “miss” on the December 2024 readout and the stock dropped. Loose dosing rules let many participants stay low, diluting the average. The result underwhelmed expectations without being weak.
- Amylin is a real second lever — and the class still carries GLP-1’s bill. Amylin signals satiety through its own hindbrain receptors, complementary to GLP-1, which is why stacking them works. But the same class costs apply: GI side effects, a lean-mass tax on any big deficit, the need to keep taking it, and cost.
- The honest bottom line: a legitimately promising next-generation combo with strong trial data — but it is early, not yet broadly available, has no clean head-to-head win over tirzepatide, and is not a free lunch on muscle.
The pipeline news, and where I actually land
Let me put my position down before I defend it. CagriSema is the real deal and the hype was still too loud, both at once. Cagrilintide — a long-acting amylin analog — is a genuine second mechanism, not a reformulation of what we already have. Bolted to semaglutide, it produced phase-3 weight loss in the low-to-mid twenties percent, which is a legitimate step up on the class. And it still landed as a “disappointment” the day the first big trial read out, because the number the market had been primed to expect was higher than the number the trial delivered. That is not a failure of the drug. It is a failure of expectation-setting. Both things are true, and any take that gives you only one of them is selling you something.
Here is the shape of it in 2026. The GLP-1 wave — semaglutide, then the dual GLP-1/GIP agonist tirzepatide — reset what “a lot of weight loss from a drug” means. The obvious next move was to add a third, distinct appetite signal on top, and amylin was the leading candidate. Novo Nordisk ran cagrilintide as a standalone, then paired it with its own semaglutide as CagriSema, and pushed the combination into the phase-3 REDEFINE program. When REDEFINE 1 read out in December 2024, the headline was a strong result that missed a stretch target, and the stock fell hard on the news7. That whipsaw — strong data, disappointed hype — is the honest frame for this whole class.
This belongs squarely in the pharmaceuticals hub, and it is the natural sequel to our flagship read on the GLP-1 era, where I argued these are cardiometabolic drugs that happen to drive weight loss. CagriSema takes that story and asks the next question: if one satiety signal gets you fifteen percent, does a second, different one get you meaningfully more? The answer the trials give is a qualified yes — more, but not the moonshot the loudest voices promised. So let me separate the parts.
Mechanism: what amylin adds that GLP-1 doesn’t
Start with the biology, because this is where the case for the combination is strongest and it is worth understanding why stacking two drugs is not just doubling one. Amylin is a peptide hormone co-secreted with insulin from the pancreatic beta cells every time you eat5. It does three things: it slows gastric emptying, it suppresses the post-meal rise in glucagon, and — the part that matters most for weight — it signals satiety through receptors in the hindbrain, in a region called the area postrema5. Cagrilintide is an engineered, long-acting version of that hormone, redesigned so a single subcutaneous dose lasts a week instead of minutes.
The reason this pairs so well with semaglutide is that GLP-1 (glucagon-like peptide-1) and amylin are different signals that both end up dialing down appetite, but through partly separate circuits. GLP-1 acts on its own receptors, including in the brain’s satiety centers; amylin acts on the amylin-receptor complex, a distinct hindbrain system5. Two levers on the same outcome, not one lever pulled twice. That is the pharmacological logic behind the combination: hit appetite from two directions and you can push weight loss further than maxing out either signal alone. The early combination work bore that out — adding cagrilintide to semaglutide drove more weight loss than semaglutide by itself in the phase-1b study4.
Amylin is a second lever on appetite, not a heavier version of the first one. That is the whole reason stacking it on GLP-1 does more than turning the GLP-1 dose up.
There is one more mechanistic detail worth flagging, because the marketing will lean on it. In preclinical work, amylin signaling reduced body weight while preserving relative lean mass — the loss skewed toward fat3. That is a real and interesting property of the molecule on its own. Whether it survives being combined with semaglutide into a regimen that drives twenty-plus percent total weight loss is a very different question, and one I come back to in the grey areas, because a large deficit has its own rules that no single molecule overrides.
What REDEFINE actually showed — and why it “underwhelmed”
Here are the numbers that should anchor everything, because the story lives in them. REDEFINE 1 enrolled 3,417 adults with overweight or obesity and at least one weight-related condition, but without type 2 diabetes, and ran once-weekly CagriSema against cagrilintide alone, semaglutide alone, and placebo for 68 weeks1. On a treatment-policy basis — counting everyone as randomized, dropouts and all — CagriSema produced about 20.4% mean weight loss, versus roughly 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and about 3% for placebo1. Among participants who stayed fully adherent, the CagriSema figure rose to 22.7%1. Sixty percent of people on the combination lost at least 20% of their body weight. Those are strong numbers by any honest standard.
So why did the December 2024 readout get written up as a letdown, and why did the stock fall? Two reasons, and both are about expectation rather than result. First, Novo Nordisk had earlier signaled an ambition in the neighborhood of 25% weight loss, so a 22.7% best case — and a 20.4% headline — landed as a shortfall against the company’s own bar, not against the field7. Second, the trial let clinicians dose flexibly, and a large share of participants did not stay on the top dose. That dilutes the average: the treatment-policy number blends people who pushed to the full dose with people who deliberately stayed lower. Strip out the confound and the drug looks stronger; on paper, the flexible-dosing average looked softer than the hype demanded. The result underwhelmed the expectation without being a weak result.
REDEFINE 2 tested a harder population — 1,206 adults with overweight or obesity and type 2 diabetes — where weight loss is reliably tougher to achieve. CagriSema delivered roughly 15.7% weight loss over 68 weeks against about 3% for placebo2. That is a very good number in people with diabetes, and consistent with the pattern across the class: diabetes blunts the response, and the combination still cleared a meaningful bar. Both trials were published in the New England Journal of Medicine in 202512.
| Trial / arm | Weight loss (68 wk) | The honest read |
|---|---|---|
| REDEFINE 1 — CagriSema, adherent1 | ≈−22.7% | Strong — but shy of the ~25% ambition |
| REDEFINE 1 — CagriSema, treatment-policy1 | ≈−20.4% | Diluted by flexible dosing |
| REDEFINE 1 — semaglutide alone1 | ≈−14.9% | The in-trial comparator to beat |
| REDEFINE 1 — cagrilintide alone1 | ≈−11.5% | Amylin monotherapy is real, modest |
| REDEFINE 2 — CagriSema (type 2 diabetes)2 | ≈−15.7% | Excellent for a diabetic population |
Now the head-to-head question everyone actually cares about: is CagriSema better than what we already have? Against semaglutide, yes — inside REDEFINE 1, the combination clearly beat semaglutide alone1. Against tirzepatide, the honest answer is we do not know, because there is no clean head-to-head trial, and tirzepatide’s own pivotal data reached the low twenties percent6. Cross-trial comparisons are not verdicts — different patients, different sites, different eras. That is why I grade the “clearly best-in-class” claim Emerging: the combination is a real advance over semaglutide, but the crown over tirzepatide has not been won on the evidence, only in the press releases.
Where this fits against the drugs you already know
We do not write dosing protocols on this site, and I am not about to start with a drug still working through regulatory review. What I can do is frame where the amylin class sits relative to what is already on pharmacy shelves, sorted by how much the evidence has your back. This is a way to think, not a regimen — and every tier assumes a prescriber, not a vendor and a screenshot. If you want to see how the established GLP-1 titration actually steps, that is what our dose planner lays out.
The current standard of care has years of trial data, real-world use, cardiovascular outcome evidence, and known cost and side-effect profiles6. If you want a weight-loss drug you can actually get, with the deepest evidence base, this is the column with hard ground under it. CagriSema is measured against this, not the other way around.
The amylin-plus-GLP-1 combination posted phase-3 numbers in the low-to-mid twenties percent, from a distinct and complementary mechanism12. This is a real advance with a real evidence base — but it is newer, in regulatory review, and carries less long-term and real-world data than the drugs above. Promising and defensible, not yet established.
Treating CagriSema as the settled king of obesity drugs, free of the class’s costs, or chasing gray-market cagrilintide to front-run approval, runs past the evidence7. There is no clean head-to-head win over tirzepatide, and the lean-mass, GI, and continued-use trade-offs of the class still apply. This is where hype wears the costume of a verdict.
The grey areas: lean mass, side effects, cost, availability
Four things the “next-gen breakthrough” framing tends to skip. First, the lean-mass tax does not vanish. It is true that amylin, on its own, tends to spare lean mass in preclinical models — the loss skews toward fat3. But CagriSema is not amylin on its own; it is a regimen driving twenty-plus percent total weight loss, and any deficit that large costs you muscle as well as fat. In the semaglutide trials, roughly a quarter to 40% of the mass lost was fat-free mass, including skeletal muscle, with facial volume among the visible casualties6. The bigger the total loss, the bigger the absolute lean-mass loss unless protein and resistance training defend it. Anyone selling the amylin class as consequence-free on muscle is overreading a preclinical property. We pull this thread apart in our reads on the lean-mass cost and how people try to clean it up and on what happens to weight when the drug stops.
Second, the side-effect profile is still the class profile. The dose-limiting problem across REDEFINE was gastrointestinal — nausea, vomiting, and related complaints — the same signature the whole GLP-1 class carries, and part of why so many participants dosed flexibly rather than pushing to the top1. Two satiety mechanisms means two contributors to that GI burden. This is not a gentler drug; it is a more powerful one, and power in this class comes with the familiar tax.
Third and fourth, cost, continued use, and availability. Like every drug in this family, CagriSema is not a course you finish — stop it and the weight tends to return, because the appetite suppression that drives the loss stops with the drug6. That means ongoing cost, indefinitely, for a branded combination that will not be cheap. And crucially, as of now it is still moving through regulatory review rather than sitting on pharmacy shelves — the December 2024 readout was a topline announcement, not a launch7. “The next big weight-loss drug” is a fair description of the pipeline. It is not yet a description of something you can pick up.
What we still don’t know
- How it stacks up head-to-head against tirzepatide. Cross-trial numbers look close, but there is no direct comparison, and until there is, “best-in-class” is a claim without a clean test behind it6.
- The real-world durability. The phase-3 data runs 68 weeks. How the loss holds, how tolerable the regimen is outside a trial, and what happens over years of use are still open — the class as a whole is young on long-horizon data1.
- The true lean-mass math in the combination. Amylin’s fat-preferential property is a monotherapy finding; how much of it survives a twenty-percent-total-loss regimen, especially in older or female users, has not been cleanly characterized with body-composition endpoints3.
- Whether flexible dosing was the story or a footnote. The REDEFINE 1 average was dragged by participants who stayed low. What a fixed high-dose regimen delivers, at what tolerability, is the number that will actually define the drug — and it is still being sorted out1.
Where this lands for me: the amylin class is a genuine advance, and CagriSema is the strongest expression of it so far — a second, complementary satiety mechanism, phase-3 data in the low-to-mid twenties percent, and a real edge over semaglutide alone. That is not nothing; that is a legitimate next generation. But the hype ran ahead of the still-good numbers, the flexible-dosing confound muddied the headline, there is no clean win over tirzepatide, and every class caveat — GI side effects, the lean-mass tax on a big deficit, indefinite use, cost — still applies. Emerging, promising, worth watching closely. Not yet the settled king, and not yet something you can hold in your hand. Respect the data, discount the hype, and take the actual decision to a prescriber when it is actually on the market.
References
- Garvey WT, Blüher M, Kandler K, Wharton S, Kang J, Lingvay I, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. DOI · PMID 40544433 · NCT05567796. (The pivotal phase-3 trial in 3,417 adults without diabetes: CagriSema produced ~20.4% mean weight loss on a treatment-policy basis and 22.7% among adherent participants over 68 weeks, versus ~14.9% for semaglutide alone, ~11.5% for cagrilintide alone, and ~3% for placebo — the source of the headline numbers and the flexible-dosing dilution.)
- Davies MJ, Bajaj HS, Broedl UC, Deenadayalan S, Fernández Landó L, Kandler K, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. DOI. (The phase-3 trial in 1,206 adults with type 2 diabetes: ~15.7% weight loss over 68 weeks versus ~3% for placebo — a strong result in the harder-to-move diabetic population.)
- Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. DOI · PMID 34798060. (Cagrilintide monotherapy: dose-dependent weight loss, ~10.8% at the top dose over 26 weeks, with the fat-preferential, relative-lean-mass-sparing property that the marketing overreads when applied to the full combination.)
- Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. DOI · PMID 33894837. (The early combination study showing cagrilintide added to semaglutide 2.4 mg drove greater weight loss than semaglutide alone — the proof-of-concept for stacking two complementary satiety signals.)
- Kruse T, Hansen JL, Dahl K, Schäffer L. Amylin as a Future Obesity Treatment. Diabetes Metab J. 2022;46(1):23-32. DOI. (The amylin biology: a pancreatic beta-cell hormone that slows gastric emptying, suppresses postprandial glucagon, and signals satiety through hindbrain receptors in the area postrema — a system distinct from and complementary to GLP-1.)
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI · PMID 33567185. (The semaglutide benchmark and the source of the class lean-mass figure — roughly 25–40% of the mass lost is fat-free mass, including skeletal muscle — plus the weight-regain-on-stopping and continued-use pattern that applies across the family.)
- Novo Nordisk A/S. CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. Company announcement, December 20, 2024. (The topline release: a strong result that landed short of the company’s earlier ~25% ambition, the readout that set off the “it underwhelmed” narrative and the share-price drop — and confirmation the program is in review, not launched.)